Facebook Linkedin

Viglobulin® Injection

(Human Normal Immunoglobulin for Intravenous Administration, BP 5%)

GENERIC NAME: Human Normal Immunoglobulin for Intravenous Administration, BP 5%

THERAPEUTIC CLASS: Biological, Immune-modulating, and Antibody-Replacement Therapeutic Agent

INDICATIONS & DOSAGE:

It is indicated for the treatment of primary immunodeficient states, such as:

  • Congenital Agammaglobulinemia: To prevent recurrent bacterial infections in patients who cannot produce their own antibodies
  • Common Variable Immunodeficiency: To reduce infection frequency and prevent long-term complications such as chronic lung disease.
  • Wiskott-Aldrich syndrome: To reduce infection risk while bridging to definitive stem cell transplantation
  • Severe Combined Immunodeficiencies: To protect against infections while awaiting curative bone marrow or stem cell transplantation.
  • B-cell Chronic Lymphocytic Leukemia (CLL): For prevention of bacterial infections in patient with hypogammaglobulinemia and/or recurrent bacterial infections associated with B- cell Chronic Lymphocytic Leukemia (CLL).
  • Idiopathic Thrombocytopenic Purpura (ITP): When a rapid rise in platelet count is needed to prevent and/or to control bleeding in a patient with Idiopathic Thrombocytopenic Purpura.
  • Kawasaki Syndrome: For the prevention of coronary artery aneurysms associated with Kawasaki syndrome.

STORAGE: Store between 2-8°C. Do not freeze. Protect from light.

PACK SIZE: 50 mL and 100 mL

DOSAGE & ADMINISTRATION:

The recommended dose of IVIg for patients with primary immunodeficiency is 300 to 600 mg/kg administered every 3 to 4 weeks. Adjust the dosage over time to achieve the desired serum through levels clinical responses. If a patient misses a dose, administer the missed dose as soon as possible, and then resume scheduled treatments every 3 or 4 weeks, as applicable.

  • Idiopathic Thrombocytopenic Purpura (ITP): The usual dosage for the treatment of acute and chronic ITP is 200-400 mg/kg daily given for 5 consecutive days. The additional doses are discontinued if an adequate response does not occur.
  • Kawasaki Syndrome: The usual dosage is 400 mg/kg daily for 5